UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 24, 2003
La Jolla Pharmaceutical Company
| Delaware | 0-24274 | 33-0361285 | ||
|
|
||||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 6455 Nancy Ridge Drive, San Diego, California | 92121 | ||
|
|
|||
| (Address of Principal Executive Offices) | (Zip Code) |
| Registrant’s telephone number, including area code: | (858) 452-6600 | |||
N/A
| Item 5. Other Events and Required FD Disclosure. | ||||||||
| Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events and Required FD Disclosure.
On July 24, 2003, the Company issued a press release announcing that, based on recent discussions with the United States Food and Drug Administration (FDA), the Company may pursue an accelerated approval for its lupus drug candidate, Riquent™, under the FDA’s Subpart H regulation. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
| (c) | Exhibits. The following exhibits are filed with this report on Form 8-K: |
| Exhibit | |||
| Number | Description of Exhibit | ||
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LA JOLLA PHARMACEUTICAL COMPANY | ||||
| Date: July 24, 2003 | By: | /s/ Steven B. Engle | ||
| Steven B. Engle | ||||
| Chairman and Chief Executive Officer | ||||
EXHIBIT INDEX
| Exhibit | ||||
| Number | Description of Exhibit | |||
| 99.1 | Press Release |